Person: ŞİMŞEK, MELİH
Now showing 1 - 8 of 8
- PublicationMetadata onlyImmunological Agents Used in Cancer Treatment(2019-02-01T00:00:00Z) Simsek, MELİH; TEKİN, Salim Başol; BİLİCİ, Mehmet; ŞİMŞEK, MELİHImmune checkpoint inhibitors (ICI) are monoclonal antibodies targeting cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), or PD-1 ligand (PD-L1). ICI are approved for the treatment of malign melanoma, non-small cell lung cancer, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, and renal cell carcinoma. They can lead to long-term anti-tumor responses by deactivating the brake mechanism in the immune system. Ipilimumab, tremelimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab are examples of ICI. CTLA-4 is a brake mechanism in immune response. Ipilimumab and tremelimumab are antibodies against CTLA-4. PD-1 is another important immune checkpoint co-inhibitor receptor that is expressed by activated T cells in the peripheral tissue. As a result of blockage of the PD-1/PD-L1 pathway, local tumor-specific immune response augments, and long-term tumor control can be achieved. In recent years, ICI are approved for the treatment of various malignities. They may be responsible for specific toxicities called immune-related adverse events (irAEs). irAEs are a consequence infiltration of normal tissues by activated T lymphocytes that are responsible for autoimmunity. Corticosteroids and anti-tumor necrosis factor agents, such as infliximab and mycophenolate mofetil, are effective in the treatment of irAEs. Immune checkpoint inhibition with monoclonal antibodies against CTLA-4 and/or PD-1/PD-L1 by single agent or combination treatments became a new option in various solid tumors. However, ICI have unique adverse events, and these adverse events should be considered in any new onset clinical situation and should be managed properly. Future prospective randomized clinical trials will clarify recent questions.
- PublicationMetadata onlyRelationship between 18-FDG-PET/CT and Clinicopathological Features and Pathological Responses in Patients with Locally Advanced Breast Cancers(2019-06-01T00:00:00Z) Yildirim, Nilgun; Simsek, MELİH; Aldemir, Mehmet Naci; BİLİCİ, Mehmet; TEKİN, Salim Başol; ŞİMŞEK, MELİHObjective: We investigated the relationship between the maximum standardized uptake value (SUVmax) of whole-body positron emission tomography/computed tomography (PET/CT) performed before treatment and the demographical and histopathological features in locally advanced breast cancer (LABC), as well as the role of PET/CT in the evaluation of pathological complete response (pCR) after neoadjuvant chemotherapy (NAC).
- PublicationMetadata onlyTreatment of patients with multiple myeloma over 65 yr: more tolerability or better response?(2015-05-01T00:00:00Z) TARKUN, PINAR; Atalay, Figen; Atesoglu, Elif Birtas; Mehtap, Ozgur; Simsek, MELİH; Terzi, Esra; GEDÜK, AYFER; Balli, Fatih; Batman, Adnan; BAYDEMİR, CANAN; Hacihanefioglu, Abdullah; ŞİMŞEK, MELİHObjectiveTwo-thirds of newly diagnosed patients with multiple myeloma (MM) are over 65yr and/or physically unfit. Such patients are not eligible for high-dose chemotherapy or stem cell transplantation. The treatment aims in these patients should be to prolong survival by obtaining the best possible response, while maintaining good tolerability. The aim of our study was to evaluate the response to treatment and treatment-related toxicities in patients treated with conventional and novel protocols.
- PublicationMetadata onlyEvaluation of 22 Primary Gastrointestinal Lymphoma Patients(2019-02-01T00:00:00Z) Yildirim, Nilgun; Turkeli, Mehmet; Akdemir, Mehmet Naci; Simsek, MELİH; TEKİN, Salim Başol; ŞİMŞEK, MELİHObjective: Primary gastrointestinal non-hodgkin lymphomas (PGI-NHL) are uncommon diseases with treatment modalities including chemotherapy, surgery, and radiotherapy. Our aim is to analyze the demographic and clinical features and treatment results of PGI-NHL.
- PublicationMetadata onlyAntibody response following Hepatitis B vaccination in peritoneal dialysis patients: does normalized urea clearance matter?(2011-01-01T00:00:00Z) DERVİŞOĞLU, ERKAN; Simsek, MELİH; Yilmaz, Ahmet; ŞİMŞEK, MELİHOBJECTIVES: Data on the factors that contribute to the antibody response to hepatitis B virus vaccination in peritoneal dialysis patients are scarce. The current study was conducted on a group of peritoneal dialysis patients to learn how the response to hepatitis B virus vaccination varies according to the patient-s clearance of urea normalized to total body water (Kt/V).
- PublicationMetadata onlyEfficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.(2015-01-01T00:00:00Z) Turkeli, Mehmet; Aldemir, Mehmet Naci; Cayir, Kerim; Simsek, MELİH; Bilici, Mehmet; Tekin, Salim Basol; Yildirim, Nilgun; Bilen, Nurhan; Makas, Ibrahim; ŞİMŞEK, MELİH
- PublicationMetadata onlyAre We Late in the Diagnosis of Malignities Occurring in Solid Organ Transplant Patients? 11 Years- Experience(2016-02-01T00:00:00Z) Turkeli, Mehmet; Simsek, MELİH; Aldemir, Mehmet Naci; Yildirim, Nilgun; ÇANKAYA, Erdem; ERDEMCİ, Burak; BİLİCİ, Mehmet; TEKİN, Salim Başol; Arslan, Sukru; KORKUT, Ercan; ŞİMŞEK, MELİHObjective: Our aim is to evaluate the frequency and characteristics of cancer in the population of patients with solid organ transplant who are under immunosuppressive medication. In this study we aimed to emphasize the importance of early diagnosis of cancer in solid organ transplant recipients. An aging population began to receive solid organ transplantation and survival times prolonged. But this had a cost and new problems came forward. Especially de novo cancers because of immunosuppressive therapy took notice. Risk of malignancy increases after organ transplantation and cancer incidence was about 2.3-3.1% in these patients including skin cancer, lung cancer, malign lymphoma, cervix cancer, kaposi sarcoma, and hepatobiliary cancer.
- PublicationMetadata onlyPrognostic Value of Baseline Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Local and Advanced Gastric Cancer Patients.(2015-01-01T00:00:00Z) Aldemir, Mehmet Naci; Turkeli, Mehmet; Simsek, MELİH; Yildirim, Nilgun; Bilen, Yusuf; Yetimoglu, Harun; Bilici, Mehmet; Tekin, Salim Basol; ŞİMŞEK, MELİH